《中国肺动脉高压诊断与治疗指南(2021版)》解读:动脉性肺动脉高压的靶向药物治疗原则

Interpretation of Guidelines for the Diagnosis and Treatment of Pulmonary Hypertension in China(2021 Edition):treatment principles of targeted drug for pulmonary arterial hypertension

动脉性肺动脉高压(PAH)以进行性肺动脉压力和肺血管阻力升高为特点,如不及时治疗,病死率较高。目前临床批准用于治疗PAH的靶向治疗药物已广泛应用于临床,而正确应用这些药物是保证治疗效果的基础。PAH患者在治疗过程中,应尽快达到并维持低危状态。在用药过程中,应遵循初始联合治疗、足量给药的原则,并根据危险分层的变化,及时调整用药方案。因此,严格密切的随访对PAH患者至关重要,本文将从PAH患者的治疗目标、药物治疗应遵循的原则以及如何根据随访结果调整治疗方案等方面,详述PAH的治疗原则。

Pulmonary arterial hypertension(PAH)is a progressive disease characterized by increasing pulmonary arterial pressure and pulmonary vascular resistance,once not be treated in time,the mortality rate increases.At present,the right application of targeted drugs which have approved for PAH and have been widely used in clinical practice is the basis for ensuring the therapeutic effect.In the course of treatment,PAH patients should be achieve and maintain low-risk status against time.During the medication period,with the principles of initial combination therapy and sufficient dosage,and balancing the changes the risk stratification,the timely adjustment of medication regimen should be performed.Therefore,strict and close follow-up is paramount for PAH patients.This paper will detail the treatment principles of PAH from aspects of treatment objectives,criterion of medication therapy,and how to adjust treatment plans based on follow-up results.